Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Veracyte, Inc. - Common Stock
(NQ:
VCYT
)
25.57
+1.34 (+5.53%)
Delayed Quote
Updated: 4:00 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veracyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)
November 10, 2026
Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher’s annual volume projections were...
From
Levi & Korsinsky, LLP
Via
GlobeNewswire
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
November 09, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
VCYT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Veracyte (VCYT)
November 09, 2026
From
Levi & Korsinsky, LLP
Via
ACCESS Newswire
VCYT Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Veracyte, Inc.
November 05, 2026
From
Ademi LLP
Via
GlobeNewswire
Veracyte Announces Third Quarter 2026 Financial Results
November 04, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
November 02, 2026
Two oral presentations mark Afirma’s strongest podium presence in recent years, alongside eight posters
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Participate in Upcoming Investor Conferences
October 29, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
October 23, 2026
STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
From
Veracyte, Inc.
Via
GlobeNewswire
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
October 19, 2026
Oral presentations include new Decipher treatment-selection evidence and an OPTIMA breast cancer health economic analysis
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
October 16, 2026
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
October 14, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
September 29, 2026
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
September 25, 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment...
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
September 14, 2026
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 01, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte Announces Second Quarter 2026 Financial Results
July 30, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Participate in Upcoming Investor Conferences
July 28, 2026
From
Veracyte, Inc.
Via
GlobeNewswire
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
July 09, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
June 01, 2026
From
Veracyte
Via
Business Wire
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
May 30, 2026
From
Veracyte, Inc.
Via
Business Wire
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
May 29, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
May 22, 2026
From
Veracyte, Inc.
Via
Business Wire
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
May 21, 2026
From
Veracyte
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
May 19, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 15, 2026
From
Veracyte, Inc.
Via
Business Wire
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
May 13, 2026
Issued on behalf of VentriPoint Diagnostics Ltd.
From
USA News Group
Via
GlobeNewswire
Veracyte Announces First Quarter 2026 Financial Results
May 05, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
April 28, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
April 14, 2026
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Kevin Haas as Chief Development and Technology Officer
March 16, 2026
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit